Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FENCNASDAQ:LENZNASDAQ:REPLNASDAQ:VIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFENCAdherex Technologies$8.63+1.9%$7.61$3.96▼$9.01$238.19M0.3992,334 shs13,334 shsLENZLENZ Therapeutics$31.53+0.2%$29.12$16.54▼$38.93$887.57M0.42190,685 shs74,653 shsREPLReplimune Group$9.39-2.7%$9.06$6.44▼$17.00$723.88M0.61871,226 shs890,588 shsVIRVir Biotechnology$5.36+1.7%$5.19$4.32▼$14.45$740.97M1.221.35 million shs544,991 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFENCAdherex Technologies-2.48%+2.05%+0.47%+69.06%+45.78%LENZLENZ Therapeutics-3.24%+7.40%-1.50%+71.83%+74.40%REPLReplimune Group+2.12%+3.88%-7.03%+35.15%+18.99%VIRVir Biotechnology-4.01%+4.56%-3.30%+1.54%-38.22%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFENCAdherex Technologies1.7204 of 5 stars3.61.00.00.00.03.30.0LENZLENZ Therapeutics1.335 of 5 stars3.60.00.00.02.20.80.0REPLReplimune Group4.1654 of 5 stars3.61.00.04.52.52.50.6VIRVir Biotechnology3.2236 of 5 stars3.42.00.00.02.23.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFENCAdherex Technologies 3.25Buy$13.0050.64% UpsideLENZLENZ Therapeutics 3.17Buy$46.6047.80% UpsideREPLReplimune Group 3.13Buy$20.83121.87% UpsideVIRVir Biotechnology 2.86Moderate Buy$32.86513.01% UpsideCurrent Analyst Ratings BreakdownLatest FENC, LENZ, REPL, and VIR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025REPLReplimune GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.006/20/2025REPLReplimune GroupCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight6/2/2025REPLReplimune GroupPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$14.00 ➝ $22.005/22/2025VIRVir BiotechnologyNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.005/20/2025FENCAdherex TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.005/14/2025FENCAdherex TechnologiesCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $13.005/12/2025VIRVir BiotechnologyNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$19.00 ➝ $14.005/8/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/17/2025VIRVir BiotechnologyThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $21.004/16/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/14/2025LENZLENZ TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight$38.00 ➝ $51.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFENCAdherex Technologies$47.54M5.01$0.03 per share272.48($0.21) per share-41.10LENZLENZ TherapeuticsN/AN/AN/AN/A$7.42 per shareN/AREPLReplimune GroupN/AN/AN/AN/A$5.40 per shareN/AVIRVir Biotechnology$74.21M9.98N/AN/A$8.35 per share0.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFENCAdherex Technologies-$440K-$0.51N/AN/AN/A-45.52%N/A-26.37%8/12/2025 (Estimated)LENZLENZ Therapeutics-$49.77M-$1.77N/AN/AN/AN/A-23.74%-22.65%8/13/2025 (Estimated)REPLReplimune Group-$247.30M-$3.07N/AN/AN/AN/A-57.98%-45.21%8/14/2025 (Estimated)VIRVir Biotechnology-$521.96M-$4.22N/AN/AN/A-2,769.04%-47.46%-39.33%7/30/2025 (Estimated)Latest FENC, LENZ, REPL, and VIR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q4 2025REPLReplimune Group-$0.75-$0.82-$0.07-$0.82N/AN/A5/13/2025Q1 2025FENCAdherex Technologies-$0.12-$0.04+$0.08-$0.04$8.18 million$8.51 million5/7/2025Q1 2025LENZLENZ Therapeutics-$0.55-$0.53+$0.02-$0.53N/AN/A5/7/2025Q1 2025VIRVir Biotechnology-$0.83-$0.88-$0.05-$0.88$8.59 million$3.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFENCAdherex TechnologiesN/AN/AN/AN/AN/ALENZLENZ TherapeuticsN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFENCAdherex TechnologiesN/A5.134.97LENZLENZ TherapeuticsN/A23.0923.09REPLReplimune Group0.177.957.95VIRVir BiotechnologyN/A6.796.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFENCAdherex Technologies55.51%LENZLENZ Therapeutics54.32%REPLReplimune Group92.53%VIRVir Biotechnology65.32%Insider OwnershipCompanyInsider OwnershipFENCAdherex Technologies10.98%LENZLENZ Therapeutics6.90%REPLReplimune Group8.80%VIRVir Biotechnology16.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFENCAdherex Technologies1027.60 million24.57 millionOptionableLENZLENZ Therapeutics11028.15 million26.20 millionN/AREPLReplimune Group21077.09 million70.30 millionOptionableVIRVir Biotechnology580138.24 million116.12 millionOptionableFENC, LENZ, REPL, and VIR HeadlinesRecent News About These CompaniesVir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJuly 7 at 2:14 AM | marketbeat.comVicki L. Sato Sells 22,000 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) StockJuly 3, 2025 | insidertrades.comInsider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) Director Sells 22,000 Shares of StockJuly 2, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by State of Alaska Department of RevenueJune 30, 2025 | marketbeat.comIs Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?June 25, 2025 | finance.yahoo.comVir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by BrokeragesJune 12, 2025 | marketbeat.comJanet Napolitano Sells 3,200 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) StockJune 3, 2025 | insidertrades.comVir Biotech at TD Cowen’s Summit: Strategic Focus on HDV and OncologyMay 29, 2025 | investing.comVir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025May 28, 2025 | businesswire.comGilead pays partner Hookipa $10M to take over HBV, HIV therapeutic vaccine programsMay 22, 2025 | fiercebiotech.comFVir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)May 22, 2025 | benzinga.comVir’s hepatitis B combo falls short in Phase II trialMay 12, 2025 | msn.comVir Biotechnology to Participate in Bank of America Securities 2025 Healthcare ConferenceMay 12, 2025 | businesswire.comVir Biotechnology First Quarter 2025 Earnings: Revenues DisappointMay 10, 2025 | finance.yahoo.comWhy Vir Biotechnology, Inc.’s (VIR) Stock Is Down 5.45%May 10, 2025 | aaii.comAQ1 2025 Vir Biotechnology Inc Earnings CallMay 10, 2025 | finance.yahoo.comVir's 'functional cure' candidate for hepatitis B misses mark in phase 2May 10, 2025 | fiercebiotech.comFVir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH StudyMay 9, 2025 | businesswire.comVir Biotechnology’s Earnings Call: Mixed Sentiment Amid ProgressMay 8, 2025 | tipranks.comVir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV TreatmentMay 8, 2025 | seekingalpha.comVir Biotechnology announces initiation of ECLIPSE Phase III program for hepatitis delta virusMay 8, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefensePayment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?By Gabriel Osorio-Mazilli | June 23, 2025View Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?FENC, LENZ, REPL, and VIR Company DescriptionsAdherex Technologies NASDAQ:FENC$8.63 +0.16 (+1.89%) As of 02:55 PM EasternFennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.LENZ Therapeutics NASDAQ:LENZ$31.53 +0.05 (+0.16%) As of 03:02 PM EasternLENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Replimune Group NASDAQ:REPL$9.39 -0.26 (-2.69%) As of 03:04 PM EasternReplimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Vir Biotechnology NASDAQ:VIR$5.36 +0.09 (+1.71%) As of 03:04 PM EasternVir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
